Salivary Gland System for the Production of Therapeutics

Information

  • Research Project
  • 6937539
  • ApplicationId
    6937539
  • Core Project Number
    R43DE017079
  • Full Project Number
    1R43DE017079-01
  • Serial Number
    17079
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/5/2005 - 19 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    SHUM, LILLIAN
  • Budget Start Date
    9/5/2005 - 19 years ago
  • Budget End Date
    8/31/2007 - 17 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/5/2005 - 19 years ago

Salivary Gland System for the Production of Therapeutics

DESCRIPTION (provided by applicant): The overall objective of this proposal is to investigate the feasibility of the ruminant salivary gland as a system for the production of therapeutic human proteins. Protein therapeutics is currently in increased demand for the treatment of disease. Existing production systems have limitations such as low capacity, high cost and lack of appropriate post-translational protein modifications. Our novel system can potentially overcome all these limitations. Our specific aim is to direct the expression of a human plasma protein to the salivary gland of transgenic goats, and to achieve secretion of the recombinant protein in saliva. Ruminants produce copius amounts of saliva daily, which is highly buffered but low in protein content. The negligible protease content allows for secretion of intact, under graded protein. These are significant advantages over the purification of recombinant proteins from proteinaceous fluids, like milk or plasma. We propose to use nuclear transfer to generate transgenic animals and have chosen to work with goats due to their short gestation period compared to cows. We will also develop a method for the long-term collection of saliva. Preliminary work in cows suggests that the salivary ducts can be readily accessed for collection. Phase I support will be used to generate salivary gland-specific transgenes, establish fetal cell lines and transgenic animals using nuclear transfer, as well as, to optimize saliva collection, processing and assay development. These data will be used to design future Phase II studies with optimized constructs to generate more animals, followed by the collection of transgenic saliva, and purification of the functional recombinant protein.

IC Name
NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH
  • Activity
    R43
  • Administering IC
    DE
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    121
  • Ed Inst. Type
  • Funding ICs
    NIDCR:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    AMERICAN INTEGRATED BIOLOGICS, INC.
  • Organization Department
  • Organization DUNS
    844753611
  • Organization City
    EAST WOODSTOCK
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    06244
  • Organization District
    UNITED STATES